Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

Thiboutot, Diane; Craft, Noah; Rißmann, Robert; Gatlik, Ewa; Souquières, Malika; Jones, Julie; Loesche, Christian

doi:10.1080/09546634.2022.2138691

Cited by 6 publications

(6 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This may be particularly relevant in those with a healthy Th17 response, which could explain why so few with TNFi-induced acne had a history of acne. However, an anti–interleukin-17 antibody failed to provide substantial improvement vs placebo in treating acne . Future work is needed to better characterize the role of TNF signaling and Th17 activity in the pathogenesis acne.…”

Section: Discussionmentioning

confidence: 99%

Role of Tumor Necrosis Factor–α Inhibitors in the Treatment and Occurrence of Acne

et al. 2023

View full text Add to dashboard Cite

ImportanceTumor necrosis factor–α inhibitors (TNFis) approved to treat several inflammatory diseases are sometimes used off label to treat severe forms of acne that are refractory to conventional therapies. However, use of TNFis can also be followed by acne occurrence, suggesting an association between TNFis and acne. Most of the literature on the topic comprises case reports and series that have not been reviewed in a systematic manner.ObjectiveTo characterize the demographic characteristics, clinical presentations, treatments, and outcomes of patients receiving TNFis to treat acne and patients who develop acne following treatment of other conditions with TNFis.Evidence ReviewA systematic literature review was performed and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses reporting guidelines. PubMed and Web of Science were searched from inception through October 17, 2022. Included studies reported on patients of any sex or age who received TNFis whose treatment was followed by resolution or occurrence of acne. Two independent reviewers screened studies based on predefined criteria and extracted data from each study, which were quantitatively combined.FindingsA total of 53 studies reporting on 64 patients who received TNFis for the treatment of acne (n = 47) or who experienced acne after treatment with TNFis for a different condition (n = 17) (mean age, 28.7 years; range, 12-64 years; 6 female individuals [8.8%]) were included. The TNFis used included adalimumab, infliximab, and etanercept. Among the 47 patients treated for acne with TNFis, most had previously received antibiotics (31 [66.0%]) or isotretinoin (32 [68.1%]). Most (44 [93.6%]) experienced partial improvement (25 [53.2%]) or clearance (19 [40.4%]) with very few adverse effects reported (3 [6.4%]). Acne manifested as part of an inflammatory syndrome for 30 patients (63.8%). Among the 17 patients treated TNFis for a different condition followed by the occurrence of acne, only 1 patient (5.9%) reported having a history of acne. Therapy with TNFis was either discontinued (8 [47.1%]) or altered (6 [35.3%]) in most patients due to acne occurrence, typically with improvement in symptoms.Conclusions and RelevanceThe results of this systematic review suggest that TNFis can be effective in treating refractory acne but can also be associated with the occurrence of acne in certain instances. Further studies elucidating the role that TNF plays in treating and inducing acne could yield insight into off-label TNFi use and acne pathogenesis, potentially guiding clinical care of patients with acne treated or induced by TNFis.

show abstract

Section: Discussionmentioning

confidence: 99%

Role of Tumor Necrosis Factor–α Inhibitors in the Treatment and Occurrence of Acne

et al. 2023

View full text Add to dashboard Cite

show abstract

“…With many cytokines also implicated in acne pathogenesis, antibody treatments have been met with mixed results. Anti-IL-17A therapy has not been found to be significantly effective in inflammatory lesions in patients with moderate to severe acne [88]. However, superoxide dismutase 3 (SOD3) has been shown to suppress TLR-2 expression in sebocytes and keratinocytes, inhibiting pro-inflammatory cytokines like TNF-α and IL-1β, and reducing lipid accumulation [89].…”

Section: Acnementioning

confidence: 99%

Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies

Tan,

Podwojniak,

Parikh

et al. 2024

CIMB

View full text Add to dashboard Cite

The evolution of personalized medicine in dermatology signifies a transformative shift towards individualized treatments, driven by the integration of biomarkers. These molecular indicators serve beyond diagnostics, offering insights into disease staging, prognosis, and therapeutic monitoring. Specific criteria guide biomarker selection, ensuring attributes like specificity, sensitivity, cost feasibility, stability, rapid detection, and reproducibility. This literature review, based on data from PubMed, SCOPUS, and Web of Science, explores biomarkers in Hidradenitis Suppurativa (HS), Psoriasis, Atopic Dermatitis (AD), Alopecia Areata (AA), Vitiligo, and Chronic Spontaneous Urticaria (CSU). In HS, TNF-α, IL-1β, and MMPs serve as biomarkers, influencing targeted therapies like adalimumab and anakinra. Psoriasis involves biomarkers such as TNF-α, IL-23, and HLA genes, shaping treatments like IL23 and IL17 inhibitors. AD biomarkers include ECP, IL-4, IL-13, guiding therapies like dupilumab and tralokinumab. For AA, lipocalin-2, cytokines, and genetic polymorphisms inform JAK inhibitors’ use. Vitiligo biomarkers range from cytokines to genetic markers like TYR, TYRP1, guiding treatments like JAK inhibitors. CSU biomarkers encompass IgE, cytokines, and autologous serum tests, influencing therapies like omalizumab and cyclosporine. Comparing conditions, common proinflammatory markers reveal limited specificity. While some biomarkers aid diagnosis and standard treatments, others hold more scientific than clinical value. Precision medicine, driven by biomarkers, has shown success in skin malignancies. Future directions involve AI-powered algorithms, nanotechnology, and multi-omics integration for personalized dermatological care.

show abstract

“…Similarly, treatments inhibiting IL-17 and IL-23, namely secukinumab and risankizumab, respectively, have been effective in managing the stubborn SAPHO syndrome [308,309], underscoring the role of the IL-17/Th17 pathway in acne pathology [85]. However, a recent clinical trial revealed that CJM112, an IL-17A inhibitor with a unique target compared with secukinumab, did not outperform a placebo in reducing inflammatory acne [310]. Additionally, an RCT examining the efficacy of the anti-IL-1β inhibitor gevokizumab (XOMA 052) has been conducted, though results are yet to be published [106].…”

Section: Emerging Therapiesmentioning

confidence: 99%

Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies

Kim,

Kim

2024

IJMS

View full text Add to dashboard Cite

Acne vulgaris is a common dermatological condition that can present across different ages but predominantly affects adolescents and young adults. Characterized by various lesion types, the pathogenesis of acne is complex, involving genetic, hormonal, microbial, and inflammatory factors. This review comprehensively addresses current and emerging acne management strategies, emphasizing both topical and systemic treatments, procedural therapies, and dietary modifications. Key topical agents include retinoids, benzoyl peroxide, antibiotics, and other specialized compounds. Systemic options like antibiotics, hormonal therapies, and retinoids offer significant therapeutic benefits, particularly for moderate to severe cases. Procedural treatments such as laser devices, photodynamic therapy, chemical peels, and intralesional injections present viable alternatives for reducing acne symptoms and scarring. Emerging therapies focus on novel biologics, bacteriophages, probiotics, and peptides, providing promising future options. This review underscores the importance of personalized approaches to treatment due to the multifaceted nature of acne, highlighting the potential of innovative therapies for improving patient outcomes.

show abstract

Anti-IL-17A blockade did not significantly reduce inflammatory lesions in a placebo-controlled pilot study in adult patients with moderate to severe acne

Cited by 6 publications

References 30 publications

Role of Tumor Necrosis Factor–α Inhibitors in the Treatment and Occurrence of Acne

Role of Tumor Necrosis Factor–α Inhibitors in the Treatment and Occurrence of Acne

Precision Dermatology: A Review of Molecular Biomarkers and Personalized Therapies

Exploring Acne Treatments: From Pathophysiological Mechanisms to Emerging Therapies

Contact Info

Product

Resources

About